A novel compound MRX-2843 more than doubled the median days of survival in laboratory models with a drug-resistant form of the acute myeloid leukemia, scientists report in a new article.
A novel compound MRX-2843 more than doubled the median days of survival in laboratory models with a drug-resistant form of the acute myeloid leukemia, scientists report in a new article.